🧬 Anti-Cancer Research Peptide
PNC-27 Dosage Protocols: All Vial Sizes
PNC-27 is a synthetic peptide combining the p53 MDM2-binding domain with a membrane-residence sequence, studied for selective induction of necrosis in cancer cells.
Choose Your Vial Size
| Vial | Final volume | Concentration | One U-100 unit | |
|---|---|---|---|---|
| 10 mg | 3 mL | 3.33 mg/mL | 33.33 mcg in 0.01 mL | Open protocol → |
| 30 mg | 3 mL | 10 mg/mL | 100 mcg in 0.01 mL | Open protocol → |
Doses are the same research amounts across sizes; the vial size changes the concentration, so syringe units differ. Always use the table for your exact vial.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
⚠ Research Use Only: PNC-27 is preclinical research only.
How This Works
PNC-27 fuses the p53 N-terminal MDM2-binding region (residues 12-26) with the leader sequence of penetratin or other membrane-residence peptides. The result selectively binds HDM-2 expressed at the cancer-cell membrane (a tumor-specific phenomenon) and triggers necrosis without affecting normal cells lacking surface HDM-2.
Potential Benefits & Side Effects
Potential Benefits
- Cancer-cell-selective necrosis in preclinical models.
- Spares normal cells lacking surface HDM-2.
- Studied in multiple solid tumor models.
Side Effect Profile
- Limited human safety data.
- Investigational compound — research only.
Lifestyle Factors
- Use is research only; not a standalone treatment.
Injection Technique
- Research protocol dictates route.
References
1
Michl J et al. 'PNC-27, a chimeric p53/penetratin peptide' — Mol Cell Biochem, 2006